SCR 116: Frontotemporal Degeneration Awareness Week.
- Session Year: 2023-2024
- House: Senate
- Latest Version Date: 2024-06-06
Current Status:
Passed
(2024-06-06: Chaptered by Secretary of State. Res. Chapter 96, Statutes of 2024.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
This measure would proclaim the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week.
This measure would proclaim the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week.
This measure would proclaim the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week.
WHEREAS, It is the custom of the Legislature to recognize official weeks that are set aside to increase awareness of serious health conditions that affect the lives of citizens of California; and
WHEREAS, Attendant to that concern and in full accord with its longstanding traditions, it is the sense of the Legislature to memorialize and to proclaim the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week in California, in conjunction with the observance of World FTD Awareness Week; and
WHEREAS, the Association for Frontotemporal Degenderation (AFTD) reports that Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern; and
WHEREAS, It takes an average of 3.6 years from start of symptoms to get an accurate diagnosis of FTD with average life expectancy of 7 to 13 years after start of symptoms; and
WHEREAS, FTD strikes people as young as 17 and as old as 87, with the largest percentage of those affected being in their 40s to 60s, rendering people in the prime of life unable to work or function normally; and
WHEREAS, FTD imposes average annual costs associated with care and living with the disease that are approximately double those of Alzheimers disease; and
WHEREAS, FTD is identified in The National Plan to Address Alzheimers Disease as a related dementia and included as a priority in the goals and strategies of the Plan to achieve the vision of a nation free of Alzheimers disease and related dementias; and
WHEREAS, The California Master Plan for Aging incorporates all ten recommendations from the Governors Task Force on Alzheimers Disease Prevention and Preparedness to help people and families living with Alzheimers and related dementia; and
WHEREAS, FTD represents an estimated 5 to 15 percent of all dementia cases and is the most common form of dementia for people under 60 years of age; and
WHEREAS, Approximately 40 percent of people with FTD have a family history of FTD or a related condition such as ALS, with about half of those found to have an inherited form accounted for by mutations in the Progranulin, C9orf72, Tau/MAPT and other rarer genes; and
WHEREAS, FTD is often misdiagnosed as a psychiatric problem or other neurodegenerative disease because of the wide range of cognitive and behavioral symptoms and their young onset; and
WHEREAS, FTD often affects a persons ability to express emotions and to show affection and empathy for loved ones; and
WHEREAS, In the behavioral variant of FTD, a persons sense of social graces and appropriate behavior can be lost, and their personality may be significantly changed; and
WHEREAS, Furthermore, in the language variants of FTD (primary progressive aphasia), a person may have trouble producing speech and understanding grammar, lose the meaning of words or become hesitant in their speech, and may eventually become mute; and
WHEREAS, In the movement variants of FTD, a person may experience muscle weakness, falling, loss of balance, difficulty making speech, difficulty swallowing, or choking; and
WHEREAS, While there has never been a global epidemiology study of FTD, it is estimated that more than 60,000 people are affected in the United States today; and
WHEREAS, AFTD is the leading national organization exclusively focused on the spectrum of FTD disorders with a mission to improve the quality of life of people affected by FTD and drive research to a cure; and
WHEREAS, It is imperative that there be greater awareness of this serious disease, and more must be done to increase activity at the local, state, and national levels; now, therefore, be it
Resolved by the Senate of the State of California, the Assembly thereof concurring, That the Legislature proclaims the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week; and be it further.
Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, It is the custom of the Legislature to recognize official weeks that are set aside to increase awareness of serious health conditions that affect the lives of citizens of California; and
WHEREAS, Attendant to that concern and in full accord with its longstanding traditions, it is the sense of the Legislature to memorialize and to proclaim the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week in California, in conjunction with the observance of World FTD Awareness Week; and
WHEREAS, the Association for Frontotemporal Degenderation (AFTD) reports that Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern; and
WHEREAS, It takes an average of 3.6 years from start of symptoms to get an accurate diagnosis of FTD with average life expectancy of 7 to 13 years after start of symptoms; and
WHEREAS, FTD strikes people as young as 17 and as old as 87, with the largest percentage of those affected being in their 40s to 60s, rendering people in the prime of life unable to work or function normally; and
WHEREAS, FTD imposes average annual costs associated with care and living with the disease that are approximately double those of Alzheimers disease; and
WHEREAS, FTD is identified in The National Plan to Address Alzheimers Disease as a related dementia and included as a priority in the goals and strategies of the Plan to achieve the vision of a nation free of Alzheimers disease and related dementias; and
WHEREAS, The California Master Plan for Aging incorporates all ten recommendations from the Governors Task Force on Alzheimers Disease Prevention and Preparedness to help people and families living with Alzheimers and related dementia; and
WHEREAS, FTD represents an estimated 5 to 15 percent of all dementia cases and is the most common form of dementia for people under 60 years of age; and
WHEREAS, Approximately 40 percent of people with FTD have a family history of FTD or a related condition such as ALS, with about half of those found to have an inherited form accounted for by mutations in the Progranulin, C9orf72, Tau/MAPT and other rarer genes; and
WHEREAS, FTD is often misdiagnosed as a psychiatric problem or other neurodegenerative disease because of the wide range of cognitive and behavioral symptoms and their young onset; and
WHEREAS, FTD often affects a persons ability to express emotions and to show affection and empathy for loved ones; and
WHEREAS, In the behavioral variant of FTD, a persons sense of social graces and appropriate behavior can be lost, and their personality may be significantly changed; and
WHEREAS, Furthermore, in the language variants of FTD (primary progressive aphasia), a person may have trouble producing speech and understanding grammar, lose the meaning of words or become hesitant in their speech, and may eventually become mute; and
WHEREAS, In the movement variants of FTD, a person may experience muscle weakness, falling, loss of balance, difficulty making speech, difficulty swallowing, or choking; and
WHEREAS, While there has never been a global epidemiology study of FTD, it is estimated that more than 60,000 people are affected in the United States today; and
WHEREAS, AFTD is the leading national organization exclusively focused on the spectrum of FTD disorders with a mission to improve the quality of life of people affected by FTD and drive research to a cure; and
WHEREAS, It is imperative that there be greater awareness of this serious disease, and more must be done to increase activity at the local, state, and national levels; now, therefore, be it
Resolved by the Senate of the State of California, the Assembly thereof concurring, That the Legislature proclaims the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week; and be it further.
Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, It is the custom of the Legislature to recognize official weeks that are set aside to increase awareness of serious health conditions that affect the lives of citizens of California; and
WHEREAS, Attendant to that concern and in full accord with its longstanding traditions, it is the sense of the Legislature to memorialize and to proclaim the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week in California, in conjunction with the observance of World FTD Awareness Week; and
WHEREAS, the Association for Frontotemporal Degenderation (AFTD) reports that Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern; and
WHEREAS, It takes an average of 3.6 years from start of symptoms to get an accurate diagnosis of FTD with average life expectancy of 7 to 13 years after start of symptoms; and
WHEREAS, FTD strikes people as young as 17 and as old as 87, with the largest percentage of those affected being in their 40s to 60s, rendering people in the prime of life unable to work or function normally; and
WHEREAS, FTD imposes average annual costs associated with care and living with the disease that are approximately double those of Alzheimers disease; and
WHEREAS, FTD is identified in The National Plan to Address Alzheimers Disease as a related dementia and included as a priority in the goals and strategies of the Plan to achieve the vision of a nation free of Alzheimers disease and related dementias; and
WHEREAS, The California Master Plan for Aging incorporates all ten recommendations from the Governors Task Force on Alzheimers Disease Prevention and Preparedness to help people and families living with Alzheimers and related dementia; and
WHEREAS, FTD represents an estimated 5 to 15 percent of all dementia cases and is the most common form of dementia for people under 60 years of age; and
WHEREAS, Approximately 40 percent of people with FTD have a family history of FTD or a related condition such as ALS, with about half of those found to have an inherited form accounted for by mutations in the Progranulin, C9orf72, Tau/MAPT and other rarer genes; and
WHEREAS, FTD is often misdiagnosed as a psychiatric problem or other neurodegenerative disease because of the wide range of cognitive and behavioral symptoms and their young onset; and
WHEREAS, FTD often affects a persons ability to express emotions and to show affection and empathy for loved ones; and
WHEREAS, In the behavioral variant of FTD, a persons sense of social graces and appropriate behavior can be lost, and their personality may be significantly changed; and
WHEREAS, Furthermore, in the language variants of FTD (primary progressive aphasia), a person may have trouble producing speech and understanding grammar, lose the meaning of words or become hesitant in their speech, and may eventually become mute; and
WHEREAS, In the movement variants of FTD, a person may experience muscle weakness, falling, loss of balance, difficulty making speech, difficulty swallowing, or choking; and
WHEREAS, While there has never been a global epidemiology study of FTD, it is estimated that more than 60,000 people are affected in the United States today; and
WHEREAS, AFTD is the leading national organization exclusively focused on the spectrum of FTD disorders with a mission to improve the quality of life of people affected by FTD and drive research to a cure; and
WHEREAS, It is imperative that there be greater awareness of this serious disease, and more must be done to increase activity at the local, state, and national levels; now, therefore, be it
Resolved by the Senate of the State of California, the Assembly thereof concurring, That the Legislature proclaims the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week; and be it further.
Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| Jun 6, 2024 | Chaptered by Secretary of State. Res. Chapter 96, Statutes of 2024. |
| Jun 6, 2024 | Enrolled and filed with the Secretary of State at 2 p.m. |
| Jun 3, 2024 | In Senate. Ordered to engrossing and enrolling. |
| May 30, 2024 | Coauthors revised. |
| May 30, 2024 | Read. Adopted. (Page 5712.) Ordered to the Senate. |
| May 20, 2024 | From committee: Be adopted. Ordered to third reading. (Ayes 9. Noes 0.) (May 20). |
| Apr 1, 2024 | Referred to Com. on RLS. |
| Mar 18, 2024 | In Assembly. Held at Desk. |
| Mar 18, 2024 | Read. Adopted. (Ayes 40. Noes 0. Page 3324.) Ordered to the Assembly. |
| Feb 29, 2024 | From committee: Ordered to third reading. |
| Feb 21, 2024 | Introduced. Referred to Com. on RLS. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 20, 2024 | Be adopted. To third reading. | Assembly Standing Committee on Rules |
Passed |
|
| Mar 18, 2024 | Senate 3rd Reading SCR116 Jones | Senate Floor |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| The Association for Frontotemporal Degeneration | ** Support |
SENATE THIRD READING
STR Bill Id:SCR 116
Author:(Jones)
As Introduced Ver:February 21, 2024
Majority vote
SUMMARY
Proclaims the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week.
Major Provisions
- Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern.
- It takes an average of 3.6 years from start of symptoms to get an accurate diagnosis of FTD with average life expectancy of seven to 13 years after start of symptoms. FTD strikes people as young as 17 and as old as 87, with the largest percentage of those affected being in their 40s to 60s, rendering people in the prime of life unable to work or function normally.
- FTD imposes average annual costs associated with care and living with the disease that are approximately double those of Alzheimer's disease.
- FTD is identified in The National Plan to Address Alzheimer's Disease as a related dementia and included as a priority in the goals and strategies of the Plan to achieve the vision of a nation free of Alzheimer's disease and related dementias.
- The California Master Plan for Aging incorporates all ten recommendations from the Governor's Task Force on Alzheimer's Disease Prevention and Preparedness to help people and families living with Alzheimer's and related dementia.
- It is imperative that there be greater awareness of this serious disease, and more must be done to increase activity at the local, state, and national levels.
COMMENTS
According to the Author
Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern. Frontotemporal Degeneration Awareness Week is crucial as it shines a spotlight on this often misunderstood disease, emphasizing detection, diagnosis, and access to care and support services.
Arguments in Support
The Association for Frontotemporal Degeneration (AFTD) writes in support: "The symptoms of FTD vary according to where in the brain the disease starts and where the loss of neurons is most concentrated. While behavior and personality changes are the most common symptoms, loss of language, the ability to communicate, impaired movement and muscle control also occur. This resolution will be instrumental in expanding awareness of FTD in the state of California."
Arguments in Opposition
None on file.
FISCAL COMMENTS
No fiscal impact. This resolution is keyed non-fiscal by Legislative Counsel.
VOTES
SENATE FLOOR: 40-0-0
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Min, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ASM RULES: 9-0-2
YES: Pacheco, Haney, Flora, Friedman, Holden, Jones-Sawyer, Maienschein, Dixon, Ting
ABS, ABST OR NV: Low, Waldron
UPDATED
VERSION: February 21, 2024
CONSULTANT: Michael Erke / RLS. / (916) 319-2800 FN: 0003460
Date of Hearing: May 20, 2024
ASSEMBLY COMMITTEE ON RULES
Blanca Pacheco, Chair
SBPCA Bill Id:SCR 116
Author:(Jones) – As Introduced Ver:
SENATE VOTE:
SUBJECT: Frontotemporal Degeneration Awareness Week.
SUMMARY: Proclaims the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week. Specifically, this resolution makes the following legislative findings:
- Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern.
- It takes an average of 3.6 years from start of symptoms to get an accurate diagnosis of FTD with average life expectancy of 7 to 13 years after start of symptoms. FTD strikes people as young as 17 and as old as 87, with the largest percentage of those affected being in their 40s to 60s, rendering people in the prime of life unable to work or function normally.
- FTD imposes average annual costs associated with care and living with the disease that are approximately double those of Alzheimer’s disease.
- FTD is identified in The National Plan to Address Alzheimer’s Disease as a related dementia and included as a priority in the goals and strategies of the Plan to achieve the vision of a nation free of Alzheimer’s disease and related dementias.
- The California Master Plan for Aging incorporates all ten recommendations from the Governor’s Task Force on Alzheimer’s Disease Prevention and Preparedness to help people and families living with Alzheimer’s and related dementia.
- It is imperative that there be greater awareness of this serious disease, and more must be done to increase activity at the local, state, and national levels.
FISCAL EFFECT: This resolution is keyed non-fiscal by Legislative Counsel.
REGISTERED SUPPORT / OPPOSITION:
Support
The Association for Frontotemporal Degeneration (AFTD)
Opposition
None on file
Analysis Prepared by: Michael Erke / RLS. / (916) 319-2800
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SCR 116 |
THIRD READING
Bill No: SCR 116
Author: Jones (R)
Introduced: 2/21/24
Vote: 21
SUBJECT: Frontotemporal Degeneration Awareness Week
SOURCE: The Association for Frontotemporal Degeneration
DIGEST:
This resolution proclaims the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week.
ANALYSIS: This resolution makes the following legislative findings:
- It is the custom of the Legislature to recognize official weeks that are set aside to increase awareness of serious health conditions that affect the lives of citizens of California.
- Attendant to that concern and in full accord with its longstanding traditions, it is the sense of the Legislature to memorialize and to proclaim the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week in California, in conjunction with the observance of World FTD Awareness Week.
- The Association for Frontotemporal Degenderation (AFTD) reports that Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern.
- It takes an average of 3.6 years from start of symptoms to get an accurate diagnosis of FTD with average life expectancy of 7 to 13 years after start of symptoms.
- FTD is often misdiagnosed as a psychiatric problem or other neurodegenerative disease because of the wide range of cognitive and behavioral symptoms and their young onset.
- FTD often affects a person’s ability to express emotions and to show affection and empathy for loved ones.
- In the behavioral variant of FTD, a person’s sense of social graces and appropriate behavior can be lost, and their personality may be significantly changed.
- Furthermore, in the language variants of FTD (primary progressive aphasia), a person may have trouble producing speech and understanding grammar, lose the meaning of words or become hesitant in their speech, and may eventually become mute.
- In the movement variants of FTD, a person may experience muscle weakness, falling, loss of balance, difficulty making speech, difficulty swallowing, or choking.
This resolution proclaims the week of September 22 to September 29, 2024, inclusive, as Frontotemporal Degeneration Awareness Week.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 2/28/24)
The Association for Frontotemporal Degeneration (source)
OPPOSITION: (Verified 2/28/24)
None received
ARGUMENTS IN SUPPORT: According to the author, “Frontotemporal Degeneration (FTD) is a terminal and incurable neurodegenerative disease affecting the frontal and temporal lobes, causing impairments to speech, personality, behavior, and motor skills that constitutes a major public health concern. FTD primarily affects individuals in their 40s to 60s but has been diagnosed in individuals as young as 14. FTD accounts for 5 to 15 percent of all dementia cases and affects an estimated 60,000 people in the US. Despite its prevalence, it is often misdiagnosed or overlooked due to its wide range of symptoms and the lack of awareness among the public and healthcare professionals. Frontotemporal Degeneration Awareness Week is crucial as it shines a spotlight on this often misunderstood disease, emphasizing the importance of
early detection, accurate diagnosis, and access to appropriate care and support services.”
Prepared by: Karen Chow / SFA / (916) 651-1520
2/28/24 9:47:44
**** END ****
Discussed in Hearing
View Older HearingsBill Author
Bill Co-Author(s):